CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
LEO 124249 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02561585
NCT02561585Phase 2Completed

Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata

LEO Pharma·interventional·Posted Sep 28, 2015·Updated Mar 6, 2025

In Brief

A Phase 2 clinical trial evaluating LEO 124249 and Vehicle for Alopecia Areata. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 28, 2015
Enrollment StartJan 1, 2016
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.8 years ago

Interventions

LEO 124249drug

Vehicleother